Clinical trials: Movement Disorders
Parkinson's Disease
Global REsponsE During iNFusIon of a gEl With LevoDopa/Carbidopa
This multicenter, post marketing observational study (PMOS) was designed to evaluate the long-term effectiveness of levodopa/carbidopa intestinal gel (DUODOPA) on motor fluctuations (duration of OFF periods) in participants with…
- Trial name
- GREENFIELD (NCT01754129)
- Volunteers
- 148 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Tardive Dyskinesia
Reducing Involuntary Movements in Participants With Tardive Dyskinesia
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of SD-809 in reducing the severity of abnormal involuntary movements of moderate to severe tardive dyskinesia.
- Trial name
- RIM-TD (NCT02198794)
- Testing
- SD-809
- Where
- 82 sites in United States, Czechia and 4 more
- Volunteers
- 343 people
- Sponsor
- Auspex Pharmaceuticals, Inc.
Parkinson Disease
Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease
The primary objective is to study the effect of SR57667B at the dose of 4 mg/d on progression of dopaminergic nigro-striatal lesions assessed by 18F-Dopa PET imaging.
- Trial name
- NCT00220272
- Testing
- SR57667B
- Where
- 7 sites in Canada, Finland and 5 more
- Volunteers
- 183 people
- Sponsor
- Sanofi
Advanced Stage Parkinson's Disease
An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.
This study is a multicenter, 9 months, open label extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.002 study.
- Trial name
- NCT00407095
- Testing
- Pardoprunox
- Where
- 87 sites in United States, Albania and 11 more
- Volunteers
- 140 people
- Sponsor
- Solvay Pharmaceuticals
Idiopathic Parkinson's Disease
Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms
The primary objective of this study was to demonstrate that Rotigotine improves non-motor symptoms compared to Placebo in subjects with Parkinson's Disease.
- Trial name
- NCT01300819
- Testing
- Rotigotine
- Where
- 87 sites in Austria, Belgium and 10 more
- Volunteers
- 349 people
- Sponsor
- UCB Pharma
Parkinson's Disease (PD), Multiple System Atrophy (MSA)
[18F]ACI-15916 PET in α-synucleinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein α-synuclein [involved in some diseases such as Parkinson's disease, Lewy body dementia and Multiple…
- Conditions
- Parkinson's Disease (PD), Multiple System Atrophy (MSA), Dementia With Lewy Bodies (DLB)
- Trial name
- NCT06891703
- Testing
- [18F]ACI-15916
- Where
- Sweden
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Healthy, Parkinson Disease
Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease
The purpose of this study is to investigate the safety of a single dose of Lu AF82422, how well it is tolerated, how the drug effects the body and what the body does to the drug in healthy non-Japanese and Japanese subjects and…
- Trial name
- NCT03611569
- Testing
- Lu AF82422
- Where
- 4 sites in United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Parkinson Disease
Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months
The objective of this study was to measure the continued efficacy of apomorphine after previous exposure of at least three months duration.
- Trial name
- NCT00200512
- Testing
- apomorphine HCl injection
- Where
- 2 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- Mylan Bertek Pharmaceuticals
Malocclusion, Clear Aligner Appliance
Impact of Aligner Replacement Protocols on Predictability of Planned Dental Movements: Evaluation of Double Aligner
The study will evaluate the impact of replacing aligners after 7 days with new aligners made of different materials on the predictability of planned dental movements.
- Conditions
- Malocclusion, Clear Aligner Appliance, Orthodontics, Tooth Movement
- Trial name
- NCT06882395
- Testing
- Group 1: FLX aligners for 10 days, Group 3: FLX aligners for 7 days, followed by new FLX aligners for 3 days., Group 2: FLX aligners worn for 7 days, followed by FLX35 aligners for 3 days.
- Where
- Brazil
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Neodent
Tourette Syndrome
Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome
This is a Phase 1b, open-label, multiple-dose study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of NBI-98854 in a total of 36 pediatric subjects with Tourette syndrome (TS).
- Trial name
- T-FORCE (NCT02256475)
- Testing
- NBI-98854
- Where
- 10 sites in United States
- Volunteers
- 36 people
- Sponsor
- Neurocrine Biosciences
Parkinson Disease
A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease
This is a phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in subjects with early untreated Parkinson's disease (PD).
- Trial name
- NCT04154072
- Testing
- NLY01, Vehicle
- Where
- 61 sites in United States, Canada
- Volunteers
- 255 people
- Sponsor
- Neuraly, Inc.
Parkinson's Disease
Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off
The purpose of this study is to test the effects of carbidopa/levodopa/entacapone compared to the effects of immediate-release carbidopa/levodopa on non-motor symptoms of end-of-dose wearing off in persons who have Parkinson's…
- Trial name
- NCT00642356
- Testing
- Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa
- Where
- 21 sites in United States
- Volunteers
- 14 people
- Sponsor
- Novartis
Parkinson's Disease
A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease
This study is conducted to evaluate the safety and tolerability of the drug product sNN0031, containing Platelet Derived Growth Factor (PDGF), when administered directly into one of the fluid filled cavities in the brain using an…
- Trial name
- NCT00866502
- Testing
- sNN0031
- Where
- 2 sites in Sweden
- Volunteers
- 12 people
- Sponsor
- Newron Sweden AB
Parkinson's Disease
Effect of Opicapone at Steady State on Warfarin Pharmacokinetics
Single-centre, open-label, fixed-sequence design consisting of 2 periods separated by a washout period of at least 14 days.
- Trial name
- NCT02305030
- Testing
- BIA 9-1067, Warfarin
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD)
The primary purpose of the study is to evaluate the safety and tolerability of single ascending doses of UCB7853 in healthy male study participants and to evaluate the safety and tolerability of multiple ascending doses of…
- Trial name
- NCT04651153
- Testing
- UCB7853
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Parkinson's Disease
Study to Evaluate SYN115 in Parkinson's Disease
This is an exploratory study to evaluate if SYN115 has an effect on Parkinson's disease as measured by clinical symptoms and brain images using magnetic resonance imaging (MRI) when a function test is administered.
- Trial name
- NCT00605553
- Testing
- Tozadenant
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Biotie Therapies Inc.
Parkinson's Disease
Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China
Rasagiline has been developed for the treatment of Parkinson's Disease (PD), as monotherapy in early PD patients not treated with levodopa, and as adjunct therapy to levodopa in levodopa-treated PD patients with motor…
- Trial name
- NCT01556165
- Testing
- rasagiline
- Where
- 15 sites in China
- Volunteers
- 130 people
- Sponsor
- H. Lundbeck A/S
Parkinson's Disease (PD)
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Injection of LY-N001 Injection for the Treatment of Moderate to Advanced Parkinson's Disease With GBA1 Mutations
This is a prospective, single-arm, single-dose clinical study designed to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of LY-N001 Injection in patients with…
- Trial name
- NCT07685444
- Testing
- LY-N001 Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Lingyi Biotech Co., Ltd.
Akathisia, Drug-Induced, Dyskinesia, Drug-Induced
Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)
This study was designed to determine if preladenant (SCH 420814, MK-3814) can reduce drug-induced involuntary movements in participants with schizophrenia or schizoaffective disorder.
- Conditions
- Akathisia, Drug-Induced, Dyskinesia, Drug-Induced, Parkinsonian Disorders
- Trial name
- NCT00686699
- Testing
- Preladenant
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple System Atrophy
Safety and Tolerability of CS10BR05 Inj. in Subjects with Multiple System Atrophy
The purpose of conducting phase 1 trial is to evaluate the safety and tolerability of autologous bone marrow-derived mesenchymal stem cells(CS10BR05) in subjects with Multiple System Atrophy.
- Trial name
- NCT03265444
- Testing
- CS10BR05
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Corestemchemon, Inc.